Cost-Effectiveness of Adding Empagliflozin to Standard Treatment for Heart Failure with Preserved Ejection Fraction Patients in China

被引：0
|
作者：
Yake Lou
Tianyang Hu
Jing Huang
机构：
[1] The Second Affiliated Hospital of Chongqing Medical University,Department of Cardiology
[2] The Second Affiliated Hospital of Chongqing Medical University,Precision Medicine Center
来源：
American Journal of Cardiovascular Drugs | 2023年 / 23卷
关键词：
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：47 / 57
页数：10
相关论文
共 50 条
  • [1] Cost-Effectiveness of Adding Empagliflozin to Standard Treatment for Heart Failure with Preserved Ejection Fraction Patients in China
    Lou, Yake
    Hu, Tianyang
    Huang, Jing
    [J]. AMERICAN JOURNAL OF CARDIOVASCULAR DRUGS, 2023, 23 (01) : 47 - 57
  • [2] Cost-Effectiveness of Empagliflozin in Patients With Heart Failure and Preserved Ejection Fraction
    Zhou, Jennifer
    Liew, Danny
    Kaye, David M.
    Zoungas, Sophia
    Stub, Dion
    [J]. CIRCULATION-CARDIOVASCULAR QUALITY AND OUTCOMES, 2022, 15 (10): : E008638
  • [3] Cost-effectiveness of Empagliflozin in Patients With Heart Failure With Preserved Ejection Fraction
    Zheng, Jimmy
    Parizo, Justin T.
    Spertus, John A.
    Heidenreich, Paul A.
    Sandhu, Alexander T.
    [J]. JAMA INTERNAL MEDICINE, 2022, 182 (12) : 1278 - 1288
  • [4] Cost-effectiveness of adding empagliflozin to the standard therapy for Heart Failure with Preserved Ejection Fraction from the perspective of healthcare systems in China
    Jiang, Yaohui
    Xie, Jun
    [J]. FRONTIERS IN CARDIOVASCULAR MEDICINE, 2022, 9
  • [5] Cost-effectiveness of adding dapagliflozin to standard treatment for heart failure with reduced ejection fraction patients in China
    Yao, Younan
    Zhang, Rongcheng
    An, Tao
    Zhao, Xinke
    Zhang, Jian
    [J]. ESC HEART FAILURE, 2020, 7 (06): : 3582 - 3592
  • [6] Cost-effectiveness of empagliflozin for the treatment of heart failure with reduced ejection fraction in China
    Sang, Haiqiang
    Wan, Yiming
    Ma, Zhenzhou
    Zhang, Shengye
    Zhao, Qiuping
    [J]. FRONTIERS IN CARDIOVASCULAR MEDICINE, 2022, 9
  • [7] COST-EFFECTIVENESS OF DAPAGLIFLOZIN VS. EMPAGLIFLOZIN IN PATIENTS WITH HEART FAILURE AND PRESERVED EJECTION FRACTION
    Rane, A.
    Nechi, R. N.
    Imam, M.
    Zoni, C. R.
    Ndikumukiza, C.
    Karaye, I
    Yunusa, I
    Alanazi, A.
    [J]. VALUE IN HEALTH, 2023, 26 (06) : S99 - S99
  • [8] Cost-effectiveness of empagliflozin in the treatment of Malaysian patients with chronic heart failure and preserved or mildly reduced ejection fraction
    Tan, Yi Jing
    Linden, Stephan
    Ong, Siew Chin
    [J]. PLOS ONE, 2024, 19 (08):
  • [9] Cost-effectiveness of adding empagliflozin to the standard therapy for Heart Failure with Preserved Ejection Fraction from the perspective of healthcare systems in China (vol 9, 946399, 2022)
    Jiang, Yaohui
    Xie, Jun
    [J]. FRONTIERS IN CARDIOVASCULAR MEDICINE, 2023, 10
  • [10] Cost-Effectiveness of Adding SGLT2 Inhibitors to Standard Treatment for Heart Failure With Reduced Ejection Fraction Patients in China
    Jiang, Yaohui
    Zheng, Rujie
    Sang, Haiqiang
    [J]. FRONTIERS IN PHARMACOLOGY, 2021, 12
12345